KR20150062912A - Composition for preventing or treating pigmentations - Google Patents
Composition for preventing or treating pigmentations Download PDFInfo
- Publication number
- KR20150062912A KR20150062912A KR1020140055107A KR20140055107A KR20150062912A KR 20150062912 A KR20150062912 A KR 20150062912A KR 1020140055107 A KR1020140055107 A KR 1020140055107A KR 20140055107 A KR20140055107 A KR 20140055107A KR 20150062912 A KR20150062912 A KR 20150062912A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- weight
- preventing
- prunella vulgaris
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 230000019612 pigmentation Effects 0.000 title claims abstract description 28
- 208000012641 Pigmentation disease Diseases 0.000 title description 27
- 239000000284 extract Substances 0.000 claims abstract description 80
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 14
- 235000010674 Prunella vulgaris Nutrition 0.000 claims abstract description 14
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims abstract description 12
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims abstract description 12
- 240000000249 Morus alba Species 0.000 claims abstract description 12
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 12
- 238000009472 formulation Methods 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 230000036541 health Effects 0.000 claims abstract description 4
- 239000003094 microcapsule Substances 0.000 claims abstract description 4
- 239000000725 suspension Substances 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 10
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 9
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- 229940069445 licorice extract Drugs 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 11
- 230000002087 whitening effect Effects 0.000 abstract description 11
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- 102000003425 Tyrosinase Human genes 0.000 description 23
- 108060008724 Tyrosinase Proteins 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 20
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 19
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 210000001364 upper extremity Anatomy 0.000 description 12
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 229940051810 licorice root extract Drugs 0.000 description 3
- 235000020725 licorice root extract Nutrition 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000005211 surface analysis Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 108010051081 dopachrome isomerase Proteins 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000239250 Copepoda Species 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/02—Antioxidant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 색소 침착의 예방·치료용 조성물에 관한 것으로서, 특히 천연 추출물을 함유하여 피부에 대한 미백 작용 및 항산화 작용이 우수한 색소 침착 예방 및 치료용 조성물에 관한 것이다.TECHNICAL FIELD The present invention relates to a composition for preventing and treating pigmentation, and more particularly, to a composition for prevention and treatment of pigmentation which is excellent in whitening action and antioxidation effect on skin by containing a natural extract.
멜라닌(melanin) 색소의 과잉 생성 및 피부 침착에 의해 초래되는 흑화현상은 멜라노사이트(melanocyte)내의 멜라노좀(melanosome)에 존재하는 티로시나아제(tyrosinase)의 활성화에 기인한다. 멜라닌은 자외선이나 외부의 자극으로부터 피부를 보호하는 역할을 하지만 필요 이상 합성이 되는 경우에는 피부에 과침착되어 기미, 주근깨 등을 형성하게 된다. 표피의 기저층에 존재하는 멜라노사이트내의 멜라노좀이라는 소포체에서 먼저 티로시나아제, TRP-1(tyrosinase related protein-1) 및 DCT(dopachrome tautomerase) 등의 효소에 의해 멜라닌이 생성되게 되는데, 특히 티로시나아제는 멜라닌 생성 첫 단계에 관여하는 중요 효소(key enzyme)로서, 티로신(tyrosine)이 도파(DOPA)를 거쳐 도파퀴논(DOPA quinone)으로 전환되고, 도파퀴논으로부터 자동 산화 반응과 효소 반응으로 도파크롬(DOPAchrome)을 거쳐 흑갈색의 공중합체인 멜라닌을 생성하게 된다.The blackening phenomenon caused by overproduction of the melanin pigment and skin deposition is due to the activation of tyrosinase present in the melanosome in the melanocyte. Melanin protects the skin from ultraviolet rays or external stimuli, but when it is synthesized more than necessary, it is over-deposited on the skin to form spots and freckles. Melanin is first produced by enzymes such as tyrosinase, tyrosinase related protein-1 (TRP-1) and DCT (dopachrome tautomerase) in melanosomes in melanocytes in the basal layer of the epidermis. In particular, tyrosinase Is a key enzyme involved in the first step of melanin production. Tyrosine is converted to DOPA quinone via DOPA and is converted to dopaquinone by automatic oxidation and enzyme reaction DOPAchrome) to produce melanin as a dark brown copolymer.
한국등록특허 제1338546호는 멜라닌의 생성을 억제하는 효과가 있는 미백 조성물에 관한 것이다. 이러한 종래의 미백 기능성 조성물은 식물 유래의 추출물을 유효 성분으로 하기 때문에 미백 기능성 및 선호도가 우수할 수 있으나, 식용이 불가능하여 외용제로 사용할 수 밖에 없도록 용도가 한정되어 있기 때문에, 경구 투여제로의 적용이 어려워 유효 성분을 다양하게 활용하기 어려운 문제점이 있다.Korean Patent No. 1338546 relates to a whitening composition having an effect of inhibiting the production of melanin. Such a conventional whitening functional composition is excellent in whitening function and preference because it is an effective ingredient of a plant-derived extract. However, since the use thereof is limited so that it can not be edible and can only be used as an external preparation, It is difficult to utilize the active ingredients in various ways.
이에 미백 기능성이 우수하여 피부 색소 침착을 예방 또는 치료할 수 있는 미백 기능성 식용 소재의 개발이 요구되고 있다.Accordingly, there is a demand for development of a whitening functional food material which is excellent in whitening function and can prevent or treat skin pigmentation.
본 발명은 상기한 바와 같은 문제점을 해결하기 위해 이루어진 것으로서, 본 발명의 목적은 상지 추출물, 자감초 추출물 및 하고초 추출물을 함유하여 피부에 대한 미백 작용 및 항산화 작용에 있어서 탁월한 효과를 나타내는 색소 침착의 예방·치료용 조성물을 제공하는 데 있다.Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made in view of the above problems, and it is an object of the present invention to provide a skin coloring composition containing a topical extract, And to provide a composition for prevention and treatment.
본 발명의 목적은 경구용 조성물로 활용이 가능한 미백 기능성 식용 소재인 색소 침착의 예방·치료용 조성물을 제공하는 데 있다.It is an object of the present invention to provide a composition for preventing and treating pigmentation, which is a whitening functional food material which can be used as an oral composition.
상기 목적을 달성하기 위한 본 발명에 의한 색소 침착의 예방·치료용 조성물은, 상지(Morus alba L.) 추출물, 자감초(Glycyrrhiza uralensis Fisch) 추출물 및 하고초(Prunella vulgaris) 추출물을 포함한다.In order to achieve the above object, the composition for preventing and treating pigmentation according to the present invention comprises Morus alba L. extract, Glycyrrhiza uralensis Fisch extract and Prunella vulgaris extract.
본 발명에 의한 색소 침착의 예방·치료용 조성물은 상지 추출물 100 중량부에 대하여 자감초 추출물 50 내지 167 중량부와 하고초 추출물 17 내지 133 중량부를 포함할 수 있다.The composition for the prevention and treatment of pigmentation according to the present invention may comprise 50 to 167 parts by weight of Zygomycorrhizae extract and 17 to 133 parts by weight of the herbal extract, based on 100 parts by weight of the topical extract.
상지 추출물, 자감초 추출물 및 하고초 추출물은 상지, 자감초 및 하고초의 건조 중량 대비 10 내지 15배 중량의 주정으로 추출된 것일 수 있다.The upper limb extract, the licorice root extract and the chrysanthemum extract may be the upper limb, the licorice root, and the liquor extracted 10 to 15 times by weight of the dry weight of the chrysanthemum.
상지 추출물, 자감초 추출물 및 하고초 추출물은 상지, 자감초 및 하고초를 각각 주정과 혼합하고 10 내지 20 시간 동안 추출하여 여과한 후, 농축하고 건조한 것일 수 있다.The upper, upper, and lower chrysanthemum extracts may be obtained by mixing the upper, middle, and lower chow with each other and extracting for 10 to 20 hours, filtering, concentrating and drying.
색소 침착의 예방·치료용 조성물은 경구용 조성물 또는 외용제일 수 있다.The composition for preventing or treating pigmentation may be an oral composition or an external preparation.
경구용 조성물은 정제, 마이크로캡슐, 현탁액, 용액 및 분말로 이루어진 그룹에서 선택된 하나의 제형으로 이루어지는 식품 또는 건강기능성 식품일 수 있다.The oral composition may be a food or health functional food consisting of one formulation selected from the group consisting of tablets, microcapsules, suspensions, solutions and powders.
외용제는 용액, 로션, 크림, 분말 및 케이크로 이루어진 그룹에서 선택된 하나의 제형으로 이루어질 수 있다.The external preparation may consist of a single formulation selected from the group consisting of solutions, lotions, creams, powders, and cakes.
본 발명에 의한 색소 침착의 예방·치료용 조성물에 의하면, 피부에 대한 미백 작용 및 항산화 작용에 있어서 탁월한 효과를 나타낸다.According to the composition for preventing and treating pigmentation according to the present invention, it exerts an excellent effect on skin whitening action and antioxidant action.
본 발명에 의하면, 식용이 가능한 식물 유래의 미백 기능성 소재를 제공함으로써, 경구 투여가 가능한 색소 침착의 예방·치료용 조성물을 제공할 수 있는 효과가 있다. INDUSTRIAL APPLICABILITY According to the present invention, it is possible to provide a composition for preventing or treating pigmentation which can be orally administered, by providing a whitening-functioning material derived from a plant capable of being edible.
도 1은 본 발명의 실시예에 의한 색소 침착의 예방·치료용 조성물의 DPPH 라디칼 소거능 평가 결과를 나타낸 도표이다.
도 2는 본 발명의 실시예에 의한 색소 침착의 예방·치료용 조성물의 티로시나아제(tyrosinase) 활성 억제 평가 결과를 나타낸 도표이다.
도 3은 본 발명의 실시예에 의한 색소 침착의 예방·치료용 조성물의 L-DOPA 활성 평가 결과를 나타낸 도표이다.1 is a graph showing the DPPH radical scavenging activity of a composition for preventing and treating pigmentation according to an embodiment of the present invention.
FIG. 2 is a graph showing the evaluation result of inhibition of tyrosinase activity of a composition for preventing or treating pigmentation according to an embodiment of the present invention. FIG.
3 is a graph showing the results of evaluation of L-DOPA activity of a composition for preventing and treating pigmentation according to an embodiment of the present invention.
이하, 첨부된 도면을 참조하여 본 발명의 바람직한 실시예를 상세히 설명한다. 이 때, 첨부된 도면에서 동일한 구성 요소는 가능한 동일한 부호로 나타내고 있음에 유의한다. 또한, 본 발명의 요지를 흐리게 할 수 있는 공지 기능 및 구성에 대한 상세한 설명은 생략할 것이다. 마찬가지 이유로 첨부 도면에 있어서 일부 구성요소는 과장되거나 생략되거나 개략적으로 도시되었다.
Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings. Note that, in the drawings, the same components are denoted by the same reference symbols as possible. Further, the detailed description of known functions and configurations that may obscure the gist of the present invention will be omitted. For the same reason, some of the components in the drawings are exaggerated, omitted, or schematically illustrated.
본 발명에 따른 색소 침착의 예방·치료용 조성물은 상지 추출물, 자감초 추출물 및 하고초 추출물을 포함하여 이루어지며, 전술한 상지 추출물, 자감초 추출물 및 하고초 추출물은 상지, 자감초 및 하고초를 주정과 1:1 내지 10의 부피비로 혼합하여 10 내지 20시간 동안 상온에서 추출하고 여과한 후, 감압 농축하고 건조하여 이루어지는 것이 바람직하다.The composition for the prevention and treatment of pigmentation according to the present invention comprises an upper body extract, a licorice root extract and a chrysanthemum extract, wherein the upper chrysanthemum extract, The mixture is mixed with the alcohol in a volume ratio of 1: 1 to 10, extracted at room temperature for 10 to 20 hours, filtered, concentrated under reduced pressure, and dried.
상지는 뽕나무과의 뽕나무(Morus alba L.) 또는 동속식물의 어린 가지를 말린 약재이다. 상지는 주로 봄에 잎이 나기 전에 가는 가지를 잘라 햇볕에 말린 것이다.The upper limb is a medicinal herb that dries the Morus alba L. or the young branches of the copepods. The upper limb is usually cut in the sun and dried in the sun before it leaves in spring.
자감초는 감초(Glycyrrhiza uralensis)를 구운 것으로 익기복맥(益氣復脈), 보비화위(補脾和胃), 견근골(堅筋骨), 장기육(長肌肉), 통구규(通九竅), 양음혈(養陰血), 제사열(除邪熱), 이백맥(利百脈), 산표한(散表寒), 해백약독(解百藥毒)하는 효능이 있는 약재이다.Glycyrrhiza uralensis is the roasted licorice, and it is believed that the roasted beef giblets, umbilical cord stones, umbilical cord muscles, long stomach muscles, It is a medicinal substance that has the efficacy that it is the efficacy which is both hematocrit (阴 阴 血), 祭 heat (邪 热 热), bacillus (肝 脉), 竹 表 寒,
하고초는 꿀풀(Prunella vulgaris var. aleutica, Prunella vulgaris var. asiatica, Prunella vulgaris var. lilacina for. albiflora)의 과수(果穗)로 간기(肝氣)를 맑게 하고 울결(鬱結)을 풀어주며, 나력, 영유, 급성 유선염, 유암(乳癌), 밤에 일어나는 안구의 통증, 빛을 보기 어렵고 눈물이 나는 증상, 머리와 눈의 현기증, 구안와사 등을 치료하는 약재이다.And purple cleanse the liver (肝 气) and release the 結 (結結) with the fruit of Prunella vulgaris var. Aleutica, Prunella vulgaris var. Asiatica, Prunella vulgaris var. Lilacina for albiflora, , Acute mastitis, breast cancer, night-time eye pain, difficult to see light and tears, dizziness of head and eye, and Guan Wasa.
주정은 에틸알콜(ethyl alcohol) 또는 에탄올(ethanol)이라고도 하며, 술의 주성분으로 각종 알코올음료 속에 함유되어 있는 것을 주정이라고도 한다. 특유한 냄새와 맛이 나는 무색액체로 상지, 자감초 및 하고초를 추출하기 위한 용매의 역할을 하며 70 내지 90%의 농도로 이루어지는 것이 바람직하다.The alcohol is also referred to as ethyl alcohol or ethanol, and the alcohol which is the main component of alcohol is contained in various alcoholic beverages. It is a colorless liquid with a peculiar smell and taste and serves as a solvent for extracting the upper part, the licorice, and the persimmon, and preferably has a concentration of 70 to 90%.
보다 구체적으로, 95% 발효주정을 정제수와 혼합하여 70 내지 90%의 농도로 묽힌 후, 상지와 자감초는 보통, 건조 중량의 10배수, 하고초는 건조 중량의 15배수로 주정을 투입하여 상온에서 10 내지 20 시간 추출하고, 카트리지필터를 사용하여 여과한다. 여액은 60℃ 이하에서 감압 농축하여 주정의 농도가 20% 이하가 되도록 농축시키고, 이를 45℃ 이하의 조건에서 동결건조하여 건조물 상태의 상지 추출물, 자감초 추출물 및 하고초 추출물을 얻는다.More specifically, a 95% fermented juice is mixed with purified water and diluted to a concentration of 70 to 90%. Then, the upper and the lower potato are usually fed at a rate of 10 times the dry weight and 15 times the dry weight, 10 to 20 hours, and filtered using a cartridge filter. The filtrate is concentrated under reduced pressure at a temperature of 60 ° C or less to concentrate the concentrate so that the concentration of the concentrate is 20% or less and freeze-dried at 45 ° C or less to obtain a dried upper limb extract,
얻어진 건조물 상태의 상지 추출물, 자감초 추출물 및 하고초 추출물은 서로 혼합하여 건조물 상태의 복합물(이하 SDW 1)을 얻을 수 있다. 상지 추출물, 자감초 추출물 및 하고초 추출물의 혼합 비율은 색소 침착의 활성지표인 티로시나아제 저해율(%), L-DOPA 저해율(%) 및 DPPH 저해율(%)이 높은 배합비율을 반응표면모델식(response surface modle equation)으로 도출하여 사용할 수 있다. 이에 따라 본 발명의 실시예에 의한 색소 침착의 예방·치료용 조성물은 상지 추출물 100 중량부에 대하여 자감초 추출물 50 내지 167 중량부와 하고초 추출물 17 내지 133 중량부를 포함할 수 있다. 보다 구체적으로는, 상지 추출물, 자감초 추출물 및 하고초 추출물을 중량비 1.5~3.0 : 1.5~2.5 : 0.5~2.0이 되도록 포함하는 것이 투입 대비 효율성의 관점에서 바람직하다.The resulting dried, upper, lower, and supernatant extracts may be mixed with each other to obtain a dry composite (hereinafter referred to as SDW 1). The mixing ratio of the upper limb extract, the licorice root extract and the chrysanthemum morifolium extract was higher than the combination ratio of tyrosinase inhibition rate (%), L-DOPA inhibition rate (%) and DPPH inhibition rate (% (response surface modle equation). Accordingly, the composition for preventing and treating pigmentation according to an embodiment of the present invention may comprise 50 to 167 parts by weight of Zygomycorrhizae extract and 17 to 133 parts by weight of an extract of Chrysanthemum morifolium, based on 100 parts by weight of the topical extract. More specifically, it is preferable from the viewpoint of efficiency of injection to include a topical extract, a licorice extract and an acaricus extract in a weight ratio of 1.5 to 3.0: 1.5 to 2.5: 0.5 to 2.0.
본원 발명의 실시예에 의한 상지 추출물, 자감초 추출물 및 하고초 추출물의 복합물 SDW1의 배합비율을 도출하기 위한 중심합성계획(central composite design)에 따른 반응표면분석 결과는 하기 표 1과 같다.The results of the reaction surface analysis according to the central composite design for deriving the blending ratio of the SDW1 complex of the upper, lower, and upper extracts according to the embodiments of the present invention are shown in Table 1 below.
No
중심합성계획에서 독립(조건)변수로 상지 추출물, 자감초 추출물, 하고초 추출물의 중량비를 -2, -1, 0, 1, 2의 5단계로 부호화하여 중심합성계획에 따라 17구간으로 설정하여 배합한다.In the central synthesis plan, the weight ratio of the upper, middle, and lower extracts as the independent (conditional) variables was coded in five steps of -2, -1, 0, 1, and 2 and set to 17 intervals according to the central synthesis plan .
배합물의 품질특성에 관련된 종속(반응)변수로서 색소침착의 실질적인 활성지표인 티로시나아제(tyrosinase) 저해율(%), L-DOPA 저해율(%), 항산화 효과인 DPPH 저해율(%)로 하였으며, 모든 실험은 3반복 측정하여 평균값을 회귀분석에 사용한다. 회귀분석에 의한 최적조건의 예측은 SAS 프로그램 (Statistical Analysis System program, version 9.1)을 이용하였고, 각 실험조건별 4차원 반응표면을 그리기 위해 매스매티카 프로그램 (Mathematica program)을 사용한다.(%), L-DOPA inhibition rate (%) and DPPH inhibition rate (%), which are actually active indicators of pigment deposition, as the dependent variables The experiment is repeated three times and the mean value is used for the regression analysis. The SAS program (Statistical Analysis System program, version 9.1) was used to predict the optimal conditions by regression analysis, and a Mathematica program was used to plot the 4-dimensional response surface for each experimental condition.
도출되는 반응표면모델식(response surface model equation)은 하기 표 2에 나타낸다.The resulting response surface model equation is shown in Table 2 below.
저해율 (%)Tyrosinase
Inhibition rate (%)
저해율 (%)L-DOPA
Inhibition rate (%)
저해율 (%)DPPH
Inhibition rate (%)
1) X1, 상지 추출물의 중량비; X2, 자감초 추출물의 중량비; X3, 하고초 추출물의 중량비
1) X 1 , weight ratio of upper limb extract; X 2 , weight ratio of the licorice extract; X 3 , and the weight ratio of the herbal extract
이 경우, 상지 추출물, 자감초 추출물 및 하고초 추출물의 투입 대비 효율성이 가장 좋은 배합비율은 상지 추출물 중량비 1.5 내지 3.0, 자감초 추출물 중량비 1.5 내지 2.5, 하고초 추출물 중량비 0.5 내지 2.0의 구간이다. 반응표면분석을 통해 얻어진 배합 구간에서의 색소 침착의 예방·치료 효능 예상 수준과 실제 수준의 비교 결과를 하기 표 3에 나타낸다.In this case, the mixing ratio of the top, bottom, and top extracts is in the range of 1.5 to 3.0, 1.5 to 2.5, and 0.5 to 2.0, respectively. Table 3 shows the results of comparison between the expected level and the actual level of the preventive / therapeutic efficacy of the pigmentation in the blending zone obtained through the reaction surface analysis.
최대값tyrosinase
Maximum value
최대값L-DOPA
Maximum value
최대값DPPH
Maximum value
표 3에 나타난 바와 같이 본 발명의 실시예에 의한 색소 침착의 예방·치료용 조성물은 상지 추출물, 자감초 추출물 및 하고초 추출물을 중량비 2.57 : 2.37 : 0.74 으로 포함할 때에 65.96%의 티로시나아제 저해활성, 58.22%의 L-DOPA 저해 활성 및 27.09%의 DPPH 억제 활성을 가진다.As shown in Table 3, when the composition for prevention and treatment of pigmentation according to the example of the present invention contains 2.57: 2.37: 0.74 weight ratio of top, twig, and chrysanthemum extracts, 65.96% of tyrosinase inhibition Activity, 58.22% L-DOPA inhibitory activity, and 27.09% DPPH inhibitory activity.
따라서 본 발명의 실시예에 의한 색소 침착의 예방·치료용 조성물은 상지(Morus alba L) 추출물, 자감초(Glycyrrhiza uralensis Fisch) 추출물, 및 하고초(Prunella vulgaris) 추출물을 중량비 1.5~3.0 : 1.5~2.5 : 0.5~2.0으로 포함하는 것이 바람직하며, 가장 바람직하게는 중량비 2.57 : 2.37 : 0.74 으로 포함하는 것이 투입 대비 효율성의 측면에서 바람직하다.Accordingly, the composition for prevention and treatment of pigmentation according to the present invention is characterized in that it contains Morus alba L extract, Glycyrrhiza uralensis Fisch extract, and Prunella vulgaris extract in a weight ratio of 1.5 to 3.0: 2.5: 0.5 to 2.0, and most preferably 2.57: 2.37: 0.74 in terms of weight ratio.
본 발명의 실시예에 의한 색소 침착의 예방·치료용 조성물은 경구용 조성물 또는 외용제인 것을 특징으로 하며, 전술한 경구용 조성물은 정제, 마이크로캡슐, 현탁액, 용액 및 분말로 이루어진 그룹에서 선택된 하나의 제형으로 이루어지는 식품 또는 건강기능성식품일 수 있으며, 상기 외용제는 용액, 로션, 크림, 분말 및 케이크로 이루어진 그룹에서 선택된 하나의 제형으로 이루어지는 것이 바람직하다. 본 발명의 실시예에서 추출물로서 포함되는 상지(Morus alba L.), 자감초(Glycyrrhiza uralensis Fisch), 하고초(Prunella vulgaris)는 식용이 가능한 식물이기 때문에, 이를 식용 주정으로 추출하여 포함하는 본 발명의 실시예에 의한 색소 침착의 예방·치료용 조성물은 가장 바람직하게는 경구용 조성물을 제조하기 위한 소재로서 활용될 수 있다.
The composition for preventing and treating pigmentation according to an embodiment of the present invention is characterized by being an oral composition or an external preparation. The oral composition may be one or more selected from the group consisting of tablets, microcapsules, suspensions, solutions and powders The composition may be a food or a health functional food comprising a formulation, and the external preparation preferably comprises one formulation selected from the group consisting of solutions, lotions, creams, powders, and cakes. Since Morus alba L., Glycyrrhiza uralensis Fisch, and Prunella vulgaris, which are included as extracts in the examples of the present invention, are edible plants, the present invention The composition for preventing and treating pigmentation according to the embodiment of the present invention may be most preferably used as a material for producing an oral composition.
이하에서는 본 발명에 따른 색소 침착의 예방·치료용 조성물을 실시예와 실험예를 들어 설명하기로 한다. 실험예 1 내지 3에 관한 결과는 도 1 내지 3에 도시한다.
Hereinafter, the composition for preventing and treating pigmentation according to the present invention will be described with reference to Examples and Experimental Examples. The results for Experimental Examples 1 to 3 are shown in Figs.
<실시예><Examples>
스테인레스 추출 용기에 상지, 자감초 및 하고초 1kg과 주정(80%) 5L를 넣고 18시간 동안 상온에서 추출하고 여과포를 이용하여 1차 여과한 후, 필터페이퍼로 2차 여과한다. 여과된 여과액은 50℃의 온도에서 감압 농축하고 동결건조법으로 분말화하여 상지 추출물, 자감초 추출물 및 하고초 추출물을 제조하며, 상지 추출물 중량비 1.5 내지 3.0, 자감초 추출물 중량비 1.5 내지 2.5 및 하고초 추출물 중량비 0.5 내지 2.0를 혼합하여 복합물(이하 SDW1)을 제조하였다. 제조된 추출물과 복합물에 증류수 또는 다이메틸설폭사이드(dimethyl sulfoxide, DMSO)를 첨가하여 1μg/㎖, 5μg/㎖, 10μg/㎖, 50μg/㎖, 100μg/㎖, 및 200μg/㎖의 농도로 용액을 각각 제조하여 실험에 사용하였다.
Add 1 kg of superfine, 1 liter of syrup, and 5 liters of syrup (80%) into a stainless steel extraction container and extract it at room temperature for 18 hours. Filter it first using filter paper, then filter it with filter paper. The filtered filtrate was concentrated under reduced pressure at a temperature of 50 캜 and powdered by freeze drying to prepare a top extract, a licorice extract and an acorn extract. The weight ratio of the top extract to the extract was 1.5 to 3.0, the weight of the extract was 1.5 to 2.5, (Weight ratio of extract: 0.5 to 2.0) were mixed to prepare a complex (hereinafter referred to as SDW1). The resulting extract and complex were dissolved in distilled water or dimethyl sulfoxide (DMSO) at a concentration of 1 μg / ml, 5 μg / ml, 10 μg / ml, 50 μg / ml, 100 μg / ml and 200 μg / Respectively.
<실험예 1><Experimental Example 1>
실험예 1에서는 DPPH 라디칼 소거능 평가를 실시하였다. 2,2-Diphenyl-1-picrylhydrazyl (DPPH) 자체는 프리 라디칼을 지니고 있는 화합물로서 수소기와 결합하게 되면 특이 색조가 감소하는 특성을 가지고 있어 항산화 활성 평가에 사용되고 있다. 이러한 원리를 이용한 항산화 활성 평가에 시험물질은 증류수나 다이메틸설폭사이드(dimethyl sulfoxide, DMSO)에 녹여 사용하였으며 0.1 mM DPPH (D-9132, SIGMA), L-Ascorbic acid (A5960, SIGMA) 등을 이용하여 시험하였다. 구체적인 시험방법은 0.1 mM DPPH를 메탄올(methanol)에 녹인 후, 농도별로 녹여 놓은 실시예 50 μL에 DPPH용액 150 μL 넣고 실온에서 (암실) 30분 반응 후 570 nm에서 측정하였으며, 자유 라디칼 소거능은 하기의 식에 준하여 계산 하였다.In Experimental Example 1, the DPPH radical scavenging ability was evaluated. 2,2-Diphenyl-1-picrylhydrazyl (DPPH) itself is a compound having free radicals, and when it binds to a hydrogen group, its specific hue decreases and it is used to evaluate antioxidant activity. The test substance was dissolved in distilled water or dimethyl sulfoxide (DMSO) to evaluate the antioxidant activity using this principle. The test substance was used by using 0.1 mM DPPH (D-9132, SIGMA) or L-ascorbic acid (A5960, SIGMA) Respectively. For the specific test method, 0.1 mM DPPH was dissolved in methanol, and 150 μL of DPPH solution was added to 50 μL of the sample dissolved in concentration. The reaction was carried out at room temperature (dark room) for 30 minutes and then at 570 nm. The free radical scavenging activity .
대조물질로서 아스코르빈산(ascorbic acid)을 사용하였으며, 시험물질로 상지 추출물, 자감초 추출물 및 하고초 추출물상지 그리고 이 추출물의 복합물인 SDW 1를 사용하여 실험을 진행하였다. 시험 결과는 도 1에 도시한다.As a control substance, ascorbic acid was used. Experiments were carried out using
시험결과, 대조군인 25 μg/ml 아스코르빈산에서는 95.23%, 12.5 μg/ml 아스코르빈산의 경우 90.16% 항산화 효능을 확인하여 기준으로 삼았다. 단일 추출물인 상지 추출물과 자감초 추출물의 경우 100 μg/ml 농도에서 각각 44.72%와 49.77% 항산화 효능을 나타내, 3.1 μg/ml 아스코르빈산의 33.88%에 상응하는 항산화 효능을 나타내었다. 그리고 하고초 추출물은 100 μg/ml에서 97.50%, 50 μg/ml에서 83.53%로 확인되어 대조군인 아스코르빈산의 25 μg/ml 및 12.5 μg/ml에 상응하는 항산화 효능을 나타내었다. 그 다음으로 상지, 자감초 및 하고초 추출물의 복합물인 SDW 1의 경우 64.51%의 항산화 효능을 나타내어 3.1 μg/ml 아스코르빈산의 33.88%의 약 2배에 상응하는 항산화 효능을 나타내었다. 따라서 100 μg/ml 하고초 추출물과 복합물인 SDW 1의 경우 항산화 효능이 우수할 것으로 사료된다. 따라서 본 발명의 실시예에 의한 색소 침착의 예방·치료용 조성물은 DPPH 라디칼 소거능 평가 결과, 항산화 활성이 우수한 것으로 나타나 피부 색소 침착의 예방 또는 치료에 효능이 있을 것으로 판단된다.
As a result, the antioxidative activity of 95.23% in 25 μg / ml ascorbic acid and 90.16% in 12.5 μg / ml ascorbic acid as the control group was used as a standard. The antioxidant activity of the extracts of the upper and upper extracts, which were the single extract, was 44.72% and 49.77% at 100 μg / ml, respectively, and 33.88% of 3.1 μg / ml ascorbic acid. The extracts of E. coli showed 97.50% and 83.53% at 100 μg / ml, respectively, and showed antioxidant activity corresponding to 25 μg / ml and 12.5 μg / ml of ascorbic acid as the control group. The antioxidant activity of
<실험예 2><Experimental Example 2>
실험예 2에서는 티로시나아제(tyrosinase) 활성억제 평가를 실시하였다. 0.1 M 인산칼륨 완충액(potassium phosphate buffer, pH 6.8) 120 μL에 일정 농도의 시료 용액 20 μL와 버섯형 티로시나아제(mushroom tyrosinase, 500 units/mL, Sigma Co., St. Louis, MO, USA) 용액 20 μL을 가하고 1.5mM의 티로신 40 μL 를 첨가하고 37℃에서 15분간 반응시켰다. 반응 후 450 nm에서 흡광도를 측정하였으며 티로시나아제 활성 억제 효과는 다음과 같이 계산하였다. 분석 결과는 도 2에 도시한다.In Experimental Example 2, inhibition of tyrosinase activity was evaluated. Mushroom tyrosinase (500 units / mL, Sigma Co., St. Louis, MO, USA) was added to 120 μL of 0.1 M potassium phosphate buffer (pH 6.8) 20 μL of the solution was added, and 40 μL of 1.5 mM tyrosine was added, followed by reaction at 37 ° C. for 15 minutes. The absorbance was measured at 450 nm after the reaction and the inhibitory effect of tyrosinase activity was calculated as follows. The results of the analysis are shown in Fig.
분석 결과, 미백효과가 잘 알려진 누룩산(kojic acid)은 2.1 μg/ml 농도에서 31.71%, 4.2 μg/ml 농도의 경우 45.73%, 8.4 μg/ml 농도에서는 67.35%, 16.6 μg/ml 농도에서 84.69% 그리고 33.3 μg/ml 농도의 경우 92.58%의 티로시나아제 활성억제 효과를 확인할 수 있었다. 단일 시료인 상지 추출물은 100 μg/ml 농도와 50 μg/ml 농도에서 각각 96.0%와 94%의 높은 티로시나아제 활성억제 효과를 나타내 33.3 μg/ml농도의 누룩산(kojic acid)와 동등한 티로시나아제 활성억제 효과가 확인되었다. 그 다음으로 100 μg/ml 농도의 자감초 추출물이 68.00%, 하고초 추출물이 37.30%의 순으로 티로시나아제 활성억제 효과를 나타내었으며, 50 μg/ml 농도의 자감초 추출물이 34.21%, 하고초 추출물이 36.8%의 순으로 티로시나아제 활성억제 효과를 나타내었다.The concentration of kojic acid, which is well known for its whitening effect, was 31.71% at 2.1 μg / ml, 45.73% at 4.2 μg / ml, 67.35% at 8.4 μg / ml and 84.69% at 16.6 μg / % And 33.3 μg / ml, respectively, of the inhibitory activity of tyrosinase activity of 92.58%. The single extract, topical extract, showed 96.0% and 94% inhibition of tyrosinase activity at a concentration of 100 μg / ml and 50 μg / ml, respectively, indicating that tyrosinase equivalent to kojic acid at a concentration of 33.3 μg / ml The activity of inhibiting the activity of the enzyme was confirmed. The results showed that the extracts of 100 μg / ml of Rhizopus japonica extract inhibited tyrosinase activity in the order of 68.00% and 37.30%, respectively. The extracts of Rhizoma extract at 50 μg / ml showed 34.21% And 36.8% of the extracts inhibited tyrosinase activity.
또한 상지, 자감초, 하고초 추출물의 복합물인 SDW 1의 경우 100 μg/ml 농도와 50 μg/ml 농도에서 각각 82.50%와 77.90%의 높은 티로시나아제 활성억제 효과가 확인되었다. 따라서 50 μg/ml 농도와 100 μg/ml 농도의 상지 추출물, 100 μg/ml 농도의 자감초 추출물과 50 μg/ml 농도와 100 μg/ml 농도 SDW 1의 경우 미백효과가 우수한 것으로 판단된다.In addition,
따라서 본 발명의 실시예에 의한 색소 침착의 예방·치료용 조성물은 티로시나아제 활성억제 평가 결과, 티로시나아제 활성 억제 효과가 우수한 것으로 나타나 피부 색소 침착의 예방 또는 치료에 효능이 있을 것으로 판단된다.
Therefore, the composition for preventing and treating pigmentation according to the embodiment of the present invention shows excellent inhibitory effect on tyrosinase activity as a result of inhibition of tyrosinase activity, and thus it is considered that it is effective for preventing or treating skin pigmentation.
<실험예 3><Experimental Example 3>
실험예 3에서는 L-DOPA 활성 평가를 실시하였다. 0.1 M 인산칼륨 완충액(potassium phosphate buffer, pH 7.0) 210 μL에 일정 농도의 시료 용액 10 μL와 버섯형 티로시나제(mushroom tyrosinase, 500 units/mL, Sigma Co., St. Louis, MO, USA) 용액 20 μL를 순서대로 넣고, 3 mM L-DOPA(L-3,4-dihydroxy phenylalanine) 용액 60 μL을 넣고 37℃에서 5분간 반응시켰다. 반응 시킨 후, 450 nm에서 흡광도를 측정하였다. 분석 결과는 도 3에 도시한다.In Experimental Example 3, the activity of L-DOPA was evaluated. Add 10 μL of the sample solution and 210 μL of mushroom tyrosinase (500 units / mL, Sigma Co., St. Louis, MO, USA) solution to 210 μL of 0.1 M potassium phosphate buffer (L-DOPA (L-3,4-dihydroxyphenylalanine) solution) was added thereto, followed by reaction at 37 ° C for 5 minutes. After the reaction, the absorbance at 450 nm was measured. The results of the analysis are shown in Fig.
분석 결과, 미백효과가 알려진 누룩산은 2.1 μg/ml 농도에서 40.41%, 4.2 μg/ml 농도의 경우 62.06%, 8.4 μg/ml 농도에서는 76.08%, 16.6 μg/ml 농도에서 83.39% 그리고 33.3 μg/ml 농도의 경우 89.12%의 L-DOPA 활성 억제 효과를 확인할 수 있었다. 단일 추출물의 경우 100 μg/ml농도와 50 μg/ml 농도의 상지 추출물은 각각 78.37%와 74.06%의 L-DOPA 활성억제 효과가 확인되었다. 이 결과는 8.4 μg/ml 누룩산(kojic acid)의 L-DOPA 활성억제 효과와 유사한 결과로 나타났다. 그 다음으로 100 μg/ml 자감초 추출물이 45.95%, 하고초 추출물이 37.88%의 순으로 L-DOPA 활성억제 효과를 나타냈다. 또한 상지, 자감초, 하고초 추출물의 복합물인 SDW 1은 100 μg/ml과 50 μg/ml 농도에서 각각 67.68%와 54.14%로 비교적 높은 L-DOPA 활성억제 효과를 확인 하였다. 따라서 L-DOPA 활성억제 효과는 50 μg/ml 농도와 100 μg/ml 농도의 상지 추출물과 복합물인 SDW 1이 우수한 것을 확인 할 수 있었다. 이 L-DOPA 활성억제 효과 결과는 50 μg/ml와 100 μg/ml 농도의 상지 추출물과 복합물인 SDW 1의 티로시나아제 활성억제 평가 결과와 같은 농도 및 시료에서도 나타남으로써 상기의 원료들이 미백효과가 높을 것으로 사료된다.As a result, the concentration of nuruk acid was found to be 40.41% at the concentration of 2.1 μg / ml, 62.06% at the concentration of 4.2 μg / ml, 76.08% at the concentration of 8.4 μg / ml, 83.39% and 33.3 μg / ml at the concentration of 16.6 μg / The inhibitory effect of L-DOPA activity of 89.12% was confirmed. In the case of single extract, L-DOPA activity was inhibited by 78.37% and 74.06% at 100 μg / ml and 50 μg / ml, respectively. This result was similar to the effect of 8.4 μg / ml kojic acid on L-DOPA activity. Next, the inhibitory effect of L-DOPA was inhibited by 45.95% of 100 μg / ml of Ganoderma lucidum extract and 37.88% of Ganoderma lucidum extract. In addition,
따라서 본 발명의 실시예에 의한 색소 침착의 예방·치료용 조성물은 L-DOPA 활성 평가 결과, L-DOPA 산화 억제 효과가 우수한 것으로 나타나 피부 색소 침착의 예방 또는 치료에 효능이 있을 것으로 판단된다.
Therefore, as a result of the L-DOPA activity evaluation, the composition for preventing and treating pigmentation according to the embodiment of the present invention shows excellent effect of inhibiting oxidation of L-DOPA, and thus it is considered to be effective for prevention or treatment of skin pigmentation.
한편, 본 명세서와 도면에 개시된 본 발명의 실시예들은 본 발명의 기술 내용을 쉽게 설명하고 본 발명의 이해를 돕기 위해 특정 예를 제시한 것일 뿐이며, 본 발명의 범위를 한정하고자 하는 것은 아니다. 여기에 개시된 실시예들 이외에도 본 발명의 기술적 사상에 바탕을 둔 다른 변형예들이 실시 가능하다는 것은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 자명한 것이다.It should be noted that the embodiments of the present invention disclosed in the present specification and drawings are only illustrative of the present invention in order to facilitate the understanding of the present invention and are not intended to limit the scope of the present invention. It will be apparent to those skilled in the art that other modifications based on the technical idea of the present invention are possible in addition to the embodiments disclosed herein.
Claims (7)
상기 상지 추출물 100 중량부에 대하여 자감초 추출물 50 내지 167 중량부와 하고초 추출물 17 내지 133 중량부를 포함하는 것을 특징으로 하는 색소 침착의 예방·치료용 조성물.The method according to claim 1,
Wherein the composition comprises 50 to 167 parts by weight of a licorice extract and 17 to 133 parts by weight of an extract of the topical extract according to 100 parts by weight of the topical extract.
상기 상지 추출물, 자감초 추출물 및 하고초 추출물은 상지, 자감초 및 하고초의 건조 중량 대비 10 내지 15배 중량의 주정으로 추출된 것을 특징으로 하는 색소 침착의 예방·치료용 조성물.The method according to claim 1,
The composition for preventing and treating pigmentation according to any one of claims 1 to 3, wherein the upper, upper, and lower extracts are extracted from the upper part of the upper part, the lower part of the lower part, and the lower part of the lower part of the upper part.
상기 상지 추출물, 자감초 추출물 및 하고초 추출물은 상지, 자감초 및 하고초를 각각 주정과 혼합하고 10 내지 20 시간 동안 추출하여 여과한 후, 농축하고 건조한 것을 특징으로 하는 색소 침착의 예방·치료용 조성물.The method according to claim 1,
Wherein the upper, upper, and lower chrysanthemum extracts are prepared by mixing the upper, the lower and the lower cholesterol, respectively, and extracting the mixture for 10 to 20 hours, and then concentrating and drying the mixture. Composition.
상기 색소 침착의 예방·치료용 조성물은 경구용 조성물 또는 외용제인 것을 특징으로 하는 색소 침착의 예방·치료용 조성물.The method according to claim 1,
Wherein the composition for preventing or treating pigmentation is an oral composition or a composition for external use.
상기 경구용 조성물은 정제, 마이크로캡슐, 현탁액, 용액 및 분말로 이루어진 그룹에서 선택된 하나의 제형으로 이루어지는 식품 또는 건강기능성 식품인 것을 특징으로 하는 색소 침착의 예방·치료용 조성물.6. The method of claim 5,
Wherein the composition for oral administration is a food or a health functional food comprising one formulation selected from the group consisting of tablets, microcapsules, suspensions, solutions and powders.
상기 외용제는 용액, 로션, 크림, 분말 및 케이크로 이루어진 그룹에서 선택된 하나의 제형으로 이루어지는 것을 특징으로 하는 색소 침착의 예방·치료용 조성물.6. The method of claim 5,
Wherein the external preparation is a single formulation selected from the group consisting of a solution, a lotion, a cream, a powder, and a cake.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130147344 | 2013-11-29 | ||
KR1020130147344 | 2013-11-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150062912A true KR20150062912A (en) | 2015-06-08 |
KR101669626B1 KR101669626B1 (en) | 2016-10-26 |
Family
ID=53500827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140055107A KR101669626B1 (en) | 2013-11-29 | 2014-05-08 | Composition for preventing or treating pigmentations |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101669626B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102014842B1 (en) * | 2018-06-29 | 2019-08-27 | (주)셀아이콘랩 | Cosmetic composition containing natural extract |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002284626A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | External skin preparation |
KR101338546B1 (en) | 2005-05-27 | 2013-12-06 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | Agent for external application to the skin |
-
2014
- 2014-05-08 KR KR1020140055107A patent/KR101669626B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002284626A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | External skin preparation |
KR101338546B1 (en) | 2005-05-27 | 2013-12-06 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | Agent for external application to the skin |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102014842B1 (en) * | 2018-06-29 | 2019-08-27 | (주)셀아이콘랩 | Cosmetic composition containing natural extract |
Also Published As
Publication number | Publication date |
---|---|
KR101669626B1 (en) | 2016-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
KR20090055309A (en) | A cosmetic composition for skin whitening and treating wrinkles | |
KR101903987B1 (en) | Functional cosmetic compositions for preventing skin aging using the natural fermented extracts and the cosmetics using the same | |
KR20170137544A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR101907921B1 (en) | Composition for preventing or ameliorating skin wrinkle comprising Schisandra chinensis extract as effective component | |
KR100604073B1 (en) | Cosmetic composition containing one selected from panax notoginseng extract, cucumis melo extract and dendrobium moniliforme extract | |
KR20170137553A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR101453258B1 (en) | Health Functional Food Composition Comprising Red Ginseng Extract, Benincasa Hispida Extract, and Apios Americana Extract for Improving Skin Beauty | |
KR102612017B1 (en) | Composition for skin improvement comprising multiple extract | |
KR101456059B1 (en) | The cosmetic composition effective in whitening and anti-aging mainly comprised of roasted licorice extract | |
KR101988295B1 (en) | Composition for skin moisturizing and anti-wrinkle comprising herbal medicine mixed extract as effective component | |
KR101980142B1 (en) | Method for producing chestnut inner shell extract with increased skin-whitening and anti-wrinkle using enzyme and autoclave treatment | |
KR20170137412A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170137549A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136911A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR101669626B1 (en) | Composition for preventing or treating pigmentations | |
KR20170136919A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20200107444A (en) | The skin cosmetic composition for anti-oxidation and anti-wrinkle of skin comprising natural complex extracts | |
KR102303400B1 (en) | Preparation Methods of Fermentation Products Using JEJU Lava Seawater, JEJU Barley Yeast and Natural Plant and Cosmetic Compositions Having Thereof | |
KR102030419B1 (en) | A composition comprising graviola having inhibitory effect on induction of grey hair and positive effect on induction of black hair | |
KR101902242B1 (en) | Composition for skin whitening | |
KR20170136933A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102016994B1 (en) | Pepper leaf extreact with improved skin whitening effect and manufacturing method thereof | |
KR20170136913A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102286083B1 (en) | Enzyme treated Krean red ginseng and Phaseolus rediatus. L., and method of making cream using thereof, and cosmetic composition comprising thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |